ABSTRACT
Objective To explore the standardized management of high-value medical consumables during medical insurance management.Methods The definition of high-value medical consumables was introduced,and the problems of high-value medical consumables were analyzed in medical insurance management.The standardized management of highvalue medical consumables was discussed from the aspects of admission and purchase management,approval of high-value medical consumables,training on medical insurance policies,construction of high-value medical consumables examination and evaluation.Results Standardized management of high-value medical consumables contributed to slowing down the increase of per capita medical consumables,controlling the amount of medical consumables during hospitalization and increasing the ratio of domestic consumables.Conclusion All the medical facilities have to avoid irrational increase of highvalue medical consumables to utilize medical insurance fund reasonably with involvement of information platform,management regulation,approval flow as well as examination and evaluation system.
ABSTRACT
Objective To explore the standardized management of high-value medical consumables during medical insurance management.Methods The definition of high-value medical consumables was introduced,and the problems of high-value medical consumables were analyzed in medical insurance management.The standardized management of highvalue medical consumables was discussed from the aspects of admission and purchase management,approval of high-value medical consumables,training on medical insurance policies,construction of high-value medical consumables examination and evaluation.Results Standardized management of high-value medical consumables contributed to slowing down the increase of per capita medical consumables,controlling the amount of medical consumables during hospitalization and increasing the ratio of domestic consumables.Conclusion All the medical facilities have to avoid irrational increase of highvalue medical consumables to utilize medical insurance fund reasonably with involvement of information platform,management regulation,approval flow as well as examination and evaluation system.
ABSTRACT
The study was purposed to investigate the effects and mechanism of bone marrow-derived mesenchymal stem cells (MSCs) on graft-versus-host desease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The model of GVHD in rat had been established by allo-HSCT with donor derived T cells. The occurence of GVHD in recipients was observed in condition with or without donor derived MSC co-transplantation. Effects of MSCs on GVHD were analyzed by model rat survival rate and pathology. Proportions of CD4+CD25+ regulatory T cells were determined by using label spleen lymphocytes and thymocytes with double fluorescent-labeled antibodies and flow cytometry. The results showed that MSCs inhibited the lethal GVHD after HSC co-transplantation and increased the survival rate. The ratio of CD4/CD8 deceased in GVHD group in different levels, as compared with that in the experimental group. The proportion of CD4+CD25+ regulatory T cells of spleen lymphocytes was 31.55 +/- 7.58% and 20.90 +/- 1.90% in experimental and GVHD groups, respectively. Similarly, the proportion of CD4+CD25+ regulatory T cells of thymocytes was 93.20 +/- 2.69% and 57.17 +/- 6.79% in experimental and the GVHD groups, respectively. Meanwhile the proportion of CD4+CD25+ regulatory T cells was higher in experimental group than that in GVHD group. It is concluded that MSCs may prevent the lethal GVHD after allo-HSC co-transplantation and raise the survival rate of model rats by acting on the CD4+CD25+ regulatory T cells in vivo.